Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Juvenile Dermatomyositis Presenting With Predominant Joint Contractures
Revista de Neurología · 26.06.2026 · 81 (6)
DOI: 10.31083/rn51324 ↗Kurz gefasst
Fallbericht in der Zeitschrift Revista de Neurología, online erschienen am 26.06.2026. Verfasst von Qiyun Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Hospital of Shanxi Medical University, 030001 Taiyuan, Shanxi, China. Hauptthemen laut MEDLINE: Dermatomyositis, Interferon-Induced Helicase, IFIH1, Autoantibodies, Contracture. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Program of Shanxi Province, Shanxi Province Higher Education "Billion Project" Science and Technology Guidance Project, Shanxi Province Higher Education “Billion Project” Science and Technology Guidance Project.
Themen: Kontrakturprophylaxe
Abstract (Originalsprache)
Introduction:Anti-melanoma differentiation-associated gene 5 (MDA5) positive juvenile dermatomyositis (JDM) (anti-MDA5+ JDM) is a distinct subtype of JDM characterized by marked clinical heterogeneity. Although cutaneous manifestations and interstitial lung disease (ILD) are well recognized, atypical musculoskeletal presentations may lead to diagnostic delay.Clinical Case:We report a 16-year-old male with anti-MDA5+ JDM who presented with progressive joint contractures as the predominant manifestation over a 2-year period. The patient also exhibited restricted mouth opening, with a classical dermatomyositis (DM) cutaneous rash absent or only mild, and proximal muscle weakness, mild to moderate. Laboratory evaluation revealed high-titer anti-MDA5 antibodies and a markedly elevated serum immunoglobulin E (IgE) level. Magnetic resonance imaging (MRI) demonstrated periarticular and soft-tissue involvement, and muscle biopsy confirmed pathological features consistent with DM. Treatment with systemic glucocorticoids in combination with methotrexate resulted in substantial improvement in joint mobility, with good tolerability during follow-up.Conclusions:Progressive contractures can occasionally become the predominant presenting manifestation in anti-MDA5+ JDM and contribute to diagnostic delay. This case underscores the importance of early evaluation for idiopathic inflammatory myopathies (IIM), including myositis-specific antibody (MSA) testing and muscle biopsy, in adolescents with unexplained progressive joint contractures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Hospital of Shanxi Medical University, 030001 Taiyuan, Shanxi, China.
- First Clinical Medical College, Shanxi Medical University, 030001 Taiyuan, Shanxi, China.
Förderung
- Fundamental Research Program of Shanxi Province
- Shanxi Province Higher Education "Billion Project" Science and Technology Guidance Project
- Shanxi Province Higher Education “Billion Project” Science and Technology Guidance Project
Zitieren
APA
Liu, Q., Zheng, K., Bai, R., Cui, Q., Wang, L., Wang, J., Liu, D., Wang, J., Zhang, W., & Chang, X. (2026). Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Juvenile Dermatomyositis Presenting With Predominant Joint Contractures. Revista de Neurología, 81(6). https://doi.org/10.31083/rn51324
Vancouver
Liu Q, Zheng K, Bai R, Cui Q, Wang L, Wang J, et al. Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Juvenile Dermatomyositis Presenting With Predominant Joint Contractures. Revista de Neurología. 2026;81(6). doi:10.31083/rn51324
BibTeX
@article{Liu2026,
author = {Liu, Qiyun and Zheng, Ke and Bai, Ruifang and Cui, Qiaoqiao and Wang, Lizhen and Wang, Jianli and Liu, Dan and Wang, Juan and Zhang, Wei and Chang, Xueli},
title = {Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Juvenile Dermatomyositis Presenting With Predominant Joint Contractures},
journal = {Revista de Neurología},
year = {2026},
volume = {81},
number = {6},
doi = {10.31083/rn51324}
}
EUVIMED